Literature DB >> 27292414

A critique of cannabis legalization proposals in Canada.

Harold Kalant1.   

Abstract

An editorial in this issue describes a cannabis policy framework document issued by a major Canadian research centre, calling for legalization of non-medical use under strict controls to prevent increase in use, especially by adolescents and young adults who are most vulnerable to adverse effects of cannabis. It claims that such a system would eliminate the severe personal, social and monetary costs of prohibition, diminish the illicit market, and provide more humane management of cannabis use disorders. It claims that experience with regulation of alcohol and tobacco will enable a system based on public health principles to control access of youth to cannabis without the harm caused by prohibition. The present critique argues that the claims made against decriminalization and for legalization are unsupported, or even contradicted, by solid evidence. Early experience in other jurisdictions suggests that legalization increases use by adolescents and its attendant harms. Regulation of alcohol use does not provide a good model for cannabis controls because there is widespread alcohol use and harm among adolescents and young adults. Government monopolies of alcohol sale have been used primarily as sources of revenue rather than for guarding public health, and no reason has been offered to believe they would act differently with respect to cannabis. Good policy decisions require extensive unbiased information about the individual and social benefits and costs of both drug use and proposed control measures, and value judgments about the benefit/harm balance of each option. Important parts of the necessary knowledge about cannabis are not yet available, so that the value judgments are not yet possible. Therefore, a better case can be made for eliminating some of the harms of prohibition by decriminalization of cannabis possession and deferring decision about legalization until the necessary knowledge has been acquired.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis policy; Cost-benefit assessment; Decriminalization; Harms caused by prohibition; Harms to adolescent users; Legalization

Mesh:

Year:  2016        PMID: 27292414     DOI: 10.1016/j.drugpo.2016.05.002

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  4 in total

1.  Cannabis is legal-why are cannabis-based pharmaceuticals still controlled?

Authors:  Wajd Alkabbani; Kevin Friesen; Shawn Bugden
Journal:  Can Pharm J (Ott)       Date:  2020-10-07

2.  Exposure to Cannabis Marketing in Social and Traditional Media and Past-Year Use Among Adolescents in States With Legal Retail Cannabis.

Authors:  Jennifer M Whitehill; Pamela J Trangenstein; Marina C Jenkins; David H Jernigan; Megan A Moreno
Journal:  J Adolesc Health       Date:  2019-11-08       Impact factor: 5.012

3.  Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.

Authors:  Elisa Pabon; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2019-08-13       Impact factor: 4.562

4.  Trends in youth cannabis use across cannabis legalization: Data from the COMPASS prospective cohort study.

Authors:  Alexandra M E Zuckermann; Katelyn V Battista; Richard E Bélanger; Slim Haddad; Alexandra Butler; Mary Jean Costello; Scott T Leatherdale
Journal:  Prev Med Rep       Date:  2021-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.